B. Dupriez

发表

Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia.

P. Morel, F. Bauters, J. Andrieux, 2002, Cancer genetics and cytogenetics.

Improving survival trends in primary myelofibrosis: an international study.

J. Reilly, P. Guglielmelli, A. Vannucchi, 2012, Journal of Clinical Oncology.

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

P. Cony-Makhoul, V. Ugo, E. Lippert, 2021, Blood advances.

Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia.

M. Le Bousse-Kerdilès, V. Praloran, S. Chevillard, 1996, Blood.

FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.

W. Vainchenker, V. Lazar, P. Guglielmelli, 2007, Cancer research.

for myelofibrosis research and treatment (IWG-MRT) response in myelofibrosis with myeloid metaplasia: On behalf of the IWG International Working Group (IWG) consensus criteria for treatment

H. Kantarjian, D. Gilliland, R. Hoffman, 2013 .

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

H. Deeg, H. Kantarjian, S. Verstovsek, 2006, Blood.

Long-term outcome of follicular low-grade lymphoma a report of 91 patients

C. Declercq, P. Morel, F. Bauters, 1993, Annals of Hematology.

The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases

P. Morel, P. Fenaux, F. Bauters, 1999, Leukemia.

Role of early splenectomy in malignant lymphomas with prominent splenic involvement (primary lymphomas of the spleen). A study of 59 cases

P. Morel, P. Fenaux, F. Bauters, 1993, Cancer.

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

C. Bogani, M. Le Bousse-Kerdilès, A. Vannucchi, 2015, Haematologica.

What are RBC-transfusion-dependence and -independence?

T. Barbui, S. Verstovsek, R. Hoffman, 2011, Leukemia research.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

P. Cony-Makhoul, L. Knoops, V. Ugo, 2017, Haematologica.

Efficacy and safety of pegylated‐interferon α‐2a in myelofibrosis: a study by the FIM and GEM French cooperative groups

P. Cony-Makhoul, L. Knoops, K. Laribi, 2013, British journal of haematology.

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

P. Morel, F. Bauters, J. Laï, 1996, Blood.

PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA

P. Fenaux, F. Bauters, J. Demory, 1989, British journal of haematology.

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.

M. Le Bousse-Kerdilès, A. Vannucchi, M. Bourgeade, 2015, Cancer research.

Transforming growth factor‐β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis

S. Chevillard, F. Bauters, J. Demory, 1994, British journal of haematology.

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

H. Dombret, X. Thomas, C. Récher, 2006, Leukemia.

Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases

P. Fenaux, F. Bauters, C. Rose, 2001, Leukemia.

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

R. Porcher, M. Robin, I. Yakoub-Agha, 2021, Bone Marrow Transplantation.

Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience

E. Solary, H. Tilly, E. Wattel, 1997 .

Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases.

R. Beuscart, P. Fenaux, F. Bauters, 1988, Blood.

p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?

C. Preudhomme, P. Fenaux, C. Roumier, 1999, Haematologica.

PEG‐IFN‐α‐2a therapy in patients with myelofibrosis

J. Rey, J. Abgrall, L. Roy, 2009 .

VIM3‐ARA C: An effective salvage regimen in refractory or recurrent aggressive non hodgkin's lymphoma. A report on 18 cases

P. Morel, P. Fenaux, F. Bauters, 2006, Hematological oncology.

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Francisco Cervantes, Giovanni Barosi, Juergen Thiele, 2007, Leukemia research.

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

H. Dombret, S. Chevret, C. Preudhomme, 2011 .

Expression of HMGA2 in PB leukocytes and purifiedCD34+ cells from controls and patients with Myelofibrosis andmyeloid metaplasia

M. Le Bousse-Kerdilès, E. Lippert, V. Praloran, 2006, Leukemia & lymphoma.

Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia

F. Bauters, J. Andrieux, C. Roumier, 2004, Genes, chromosomes & cancer.

Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases.

P. Morel, L. Fouillard, L. Douay, 1995, Leukemia.

Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, É. Lepage, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High incidence of lymphoid infiltration on labial salivary gland biopsy in non‐Hodgkin's lymphomas: clinical implications

P. Morel, F. Bauters, A. Janin, 1993, British journal of haematology.

Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases

K. Hoang-Xuan, V. Leblond, C. Houillier, 2012, Haematologica.

Cryptic 6p21.3 duplications and triplication involving HMGA1 partially masked by add 6p in four cases of myelodysplasia.

F. Bauters, J. Andrieux, N. Dastugue, 2006, Cancer genetics and cytogenetics.

Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.

H. Dombret, H. Tilly, S. Chevret, 2004, Blood.

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

K. Hoang-Xuan, M. Sanson, O. Casasnovas, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases].

F. Bauters, B. Dupriez, P. Danjou, 1993, Journal de Chirurgie.

Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis

M. Le Bousse-Kerdilès, V. Praloran, S. Chevillard, 1997, British journal of haematology.

Treatment of severe aplastic anemia with antilymphocyte globulin and androgens: A report on 33 patients

P. Morel, P. Fenaux, C. Gardin, 1991, Annals of Hematology.

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, B. Coiffier, H. Tilly, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH87 protocol group 3: A gela study

P. Gaulard, B. Coiffier, H. Tilly, 1996 .

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

P. Campbell, K. Döhner, H. Döhner, 2006, Blood.

Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.

S. Koscielny, C. Sebban, J. Bosq, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, A. Delannoy, C. Haioun, 1994, British Journal of Cancer.

Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups

E. Montserrat, J. Reilly, G. Barosi, 1998, British journal of haematology.

Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, P. Biron, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1997, Leukemia & lymphoma.

Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients.

C. Gisselbrecht, É. Lepage, P. Morel, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients.

A. Duhamel, P. Morel, B. Hivert, 2010, Blood.

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

P. Campbell, S. Verstovsek, R. Mesa, 2008, Leukemia.

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

R. Mesa, J. Reilly, G. Barosi, 2008, Blood.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia

B. Drénou, T. Leblanc, L. Adès, 2017, Haematologica.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Francisco Cervantes, Giovanni Barosi, Juergen Thiele, 2013, Blood.

Congenital diserythropoietic anemia type I

P. Morel, P. Fenaux, T. Facon, 1990, Blut.

and Treatment study of the International Working Group for Myelofibrosis Research New prognostic scoring system for primary myelofibrosis based on a

R. Mesa, J. Reilly, G. Barosi, 2013 .

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

M. Le Bousse-Kerdilès, G. Barosi, F. Ilariucci, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

R. Porcher, M. Robin, I. Yakoub-Agha, 2013 .

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).

M. Griesshammer, J. Reilly, M. Le Bousse-Kerdilès, 2005, Blood.

Short communication Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia

P. Morel, F. Bauters, J. Andrieux, 2002 .

Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.

P. Gaulard, C. Gisselbrecht, É. Lepage, 2001, The hematology journal : the official journal of the European Haematology Association.

Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis.

S. Verstovsek, R. Mesa, J. Reilly, 2007 .

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM).

P. Cony-Makhoul, B. Drénou, Anne Quinquenel, 2012 .

Cytological and ultrastructural assessment of free crystals or precipitates associated with pseudoleukocytosis and pseudothrombocytosis in cryoglobulinemia.

B. Jude, P. Fenaux, M. Zandecki, 1989, Nouvelle revue francaise d'hematologie.

Alternating Chemotherapy Does Not Improve Results in Poor-prognosis Aggressive Lymphomas - Lnh87 Protocol Group-3 - a Gela Study

P. Gaulard, B. Coiffier, H. Tilly, 1993 .

PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM).

J. Rey, J. Abgrall, L. Roy, 2009, British journal of haematology.

Efficacy and Safety of Peg-Interferon-α2a In Myelofibrosis: a Study of the FIM and GEM French Cooperative Groups

J. Rey, J. Abgrall, L. Roy, 2010 .

C. Lorthois, C. Preudhomme, P. Fenaux, 1991, Leukemia & lymphoma.

[Primary cardiac lymphoma. A new case].

D. Smadja, P. Fenaux, F. Bauters, 1990, Annales de medecine interne.